| Ytd | -48.10% | |
| 1y | -81.60% |
| Open | 2.05 | Prev Close | 2.00 | Low | 2.05 | High | 2.05 | Mkt Cap | 4.96M |
| Vol | 741.00 | Avg Vol | 100.29K | EPS | -1.49 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.87 | Short Ratio | 2.21 | Inst. Own | 0.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.16 | 200-d Avg | 3.37 | 1yr Est | 0.00 |
KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“Bi
KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) to
Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluat
BioNexus Gene Lab (NASDAQ: BGLC - Get Free Report) and Beauty Health (NASDAQ: SKIN - Get Free Report
BioNexus Gene Lab Corp. (NASDAQ: BGLC - Get Free Report) was up 1.7% during trading on Friday. The s
BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company"), a technology-d
KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“B
As previously disclosed, commencing in the third quarter of fiscal year 2025, the Company's Boar
KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("B
SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”),
BioNexus Gene Lab Corp. ("BGLC") today announced that it has executed an Exclusive Intellect
KUALA LUMPUR, Malaysia and SINGAPORE, Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BG
BioNexus Gene Lab Corp. ("BGLC, ("BGLC," NASDAQ:BGLC) today announced it has entered int
KUALA LUMPUR, Malaysia and SINGAPORE, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BG
BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a biotechnology
KUALA LUMPUR, Malaysia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“B
BioNexus Gene Lab (NASDAQ: BGLC - Get Free Report) and PACS Group (NYSE: PACS - Get Free Report) are
BioNexus Gene Lab Corp (NASDAQ:BGLC, "BGLC", or the "Company")), today announced tha
Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC's Biotech Footprint in As
KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: B